Want to dive into Scott Alexander's work and his thousands of blog posts? This fan website lets you sort and do semantic search through the whole codex. Enjoy!
| Date | ||
| Length | ||
| Likes | ||
| Comments |
Scott analyzes the implications of the FDA ending compounded GLP-1 weight loss drugs, which have provided a cheaper alternative to official channels for the past three years, and examines various responses from both compounding pharmacies and pharmaceutical companies.
Scott Alexander examines how compounding pharmacies are producing cheaper versions of GLP-1 agonist drugs, exploring the economics, safety, and future implications of this practice.